A Phase 2 interventional study of pemetrexed and cisplatin in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 18 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-18.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 8 of them phase 3. Cisplatin · Carcinoma, Non-Small-Cell Lung.
Among the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, this one is the 57th largest by enrollment of the 198 interventional ones that give a count, is one of 18 that started in 2005, is one of 115 in phase 2, and was the 61st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →13 of the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
The Affiliated Hospital of Qingdao University · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Belgium, Canada and 9 more countries
Ages 18–95
Hunan Province Tumor Hospital · Sites in China
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 132 · Phase 3 47 · Phase 4 3
First in 1994; this study’s year is marked. 18 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 58 across the 198 interventional studies. Of the 159 that completed or were terminated, 62 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 213 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 61st largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2005, is one of 73 in phase 2, and was the 35th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
4 of the studies testing cisplatin in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT02889666Shanghai Jiao Tong University School of MedicineA Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer | 2026-12 |
| NCT04253964Wake Forest University Health SciencesPilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, open-label, two-arm, randomized, parallel Phase 2 feasibility study of pemetrexed in combination with either cisplatin (Arm A) or carboplatin (Arm B) as adjuvant combination-chemotherapy in participants with completely resected, stage Ib or IIa/IIb non-small cell lung cancer (NSCLC).
A two-stage design will be employed independently for both treatment arms, with the possibility of stopping each treatment early for lack of feasibility.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed · Drug: cisplatin
Drug: pemetrexed · Drug: carboplatin
500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 4 cycles
Also known as: LY231514, Alimta
75 mg/m\^2, intravenous (IV), every 21 days x 4 cycles
area under the curve (AUC) 5 milligrams per milliliter\*minute (mg/ml\*min), intravenous (IV), every 21 days x 4 cycles
The Feasibility of Post-Surgery Chemotherapy
Feasibility was measured by completion of 4 treatment cycles without remaining toxicities \>=Grade 3 at 30 days after last infusion.
Time frame: every 21-day cycle for 4 cycles up to 30 days after last infusion
Grade III/IV Adverse Events
Number of participants experiencing Grade III/IV hematologic and non-hematologic adverse events possibly related to study drug or protocol procedures in this study.
Time frame: every 21-day cycle for 4 cycles
Overall Survival at 3 Years
For each treatment arm, the Kaplan-Meier technique was used to estimate the 3 year survival rate. Results are presented as probability (%) of survival at 3 years. Overall survival is the duration from enrollment to death. For participants not known to have died, overall survival was censored at the last known alive date.
Time frame: baseline to date of death from any cause, assessed at 3 years
3 Year Disease-Free Survival: Probability of Disease-Free Survival at 3 Years
For each treatment arm, the Kaplan-Meier technique was used to estimate the 3 year disease-free rate. Disease-free survival is defined as the time from enrollment to the first observation of disease progression, or death due to any cause. For participants not known to have died and to have had recurrent disease, disease-free survival was censored at the date of the last participant contact with No Recurrence status. Results are presented as probability (%) of disease-free survival at 3 years.
Time frame: length of time disease free, assessed at 3 years
Overall Survival at 6 Years
For each treatment arm, the Kaplan-Meier technique was used to estimate the 6 year survival rate. Results are presented as probability (%) of survival at 6 years. Overall survival is the duration from enrollment to death. For participants not known to have died, overall survival was censored at the last known alive date.
Time frame: Baseline to date of death from any cause assessed at 6 years
| Milestone | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| Started | 63 | 59 |
| Completed | 45 | 49 |
| Not completed | 18 | 10 |
| Withdrew: Adverse event | 9 | 3 |
| Withdrew: Withdrawal by subject | 7 | 3 |
| Withdrew: Physician decision | 2 | 3 |
| Withdrew: Protocol violation | 0 | 1 |
Feasibility was measured by completion of 4 treatment cycles without remaining toxicities \>=Grade 3 at 30 days after last infusion.
| participants | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| Participants "feasible" | 38 | 27 |
| Non-feasible = Early Discontinuation | 18 | 6 |
| Non-feasible = Lost to Follow-up | 1 | 2 |
| Non-feasible = Remaining Grade 3/4 Toxicity | 4 | 3 |
| Non-feasible = Underdosage (<95% intended dose) | 5 | 19 |
Number of participants experiencing Grade III/IV hematologic and non-hematologic adverse events possibly related to study drug or protocol procedures in this study.
| participants | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| Neutropenia | 9 | 6 |
| Anaemia | 0 | 3 |
| Thrombocytopenia | 0 | 3 |
| Febrile neutropenia | 0 | 2 |
| Leukopenia | 0 | 1 |
| Lymphopenia | 1 | 0 |
| Neutrophil count decreased | 1 | 6 |
| Haemoglobin count decreased | 0 | 2 |
| Platelet count decreased | 1 | 1 |
| White blood cell count decreased | 0 | 2 |
| Asthenia | 4 | 2 |
| Nausea | 3 | 0 |
| Vomiting | 3 | 0 |
| Fatigue | 0 | 2 |
| Catheter related infection | 1 | 0 |
| Gamma-glutamyltransferase increased | 1 | 0 |
| Anorexia | 1 | 0 |
| Hyperglycaemia | 1 | 0 |
| Hyperkalaemia | 1 | 0 |
| Psychotic disorder | 1 | 0 |
For each treatment arm, the Kaplan-Meier technique was used to estimate the 3 year survival rate. Results are presented as probability (%) of survival at 3 years. Overall survival is the duration from enrollment to death. For participants not known to have died, overall survival was censored at the last known alive date.
| percent probability of survival (%) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| Overall Survival at 3 Years | 82.0 (72.4 to 91.6) | 83.2 (73.2 to 93.2) |
For each treatment arm, the Kaplan-Meier technique was used to estimate the 3 year disease-free rate. Disease-free survival is defined as the time from enrollment to the first observation of disease progression, or death due to any cause. For participants not known to have died and to have had recurrent disease, disease-free survival was censored at the date of the last participant contact with No Recurrence status. Results are presented as probability (%) of disease-free survival at 3 years.
| probability of disease-free survival (%) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| 3 Year Disease-Free Survival: Probability of Disease-Free Survival at 3 Years | 61.2 (48.3 to 74.0) | 67.3 (54.5 to 80.1) |
For each treatment arm, the Kaplan-Meier technique was used to estimate the 6 year survival rate. Results are presented as probability (%) of survival at 6 years. Overall survival is the duration from enrollment to death. For participants not known to have died, overall survival was censored at the last known alive date.
| percent probability of survival (%) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| Overall Survival at 6 Years | 72.6 (59.3 to 85.9) | 83.2 (73.2 to 93.2) |
Collected over baseline through four 21-day cycles and up to 30 days of follow-up after last infusion. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Cisplatin | — | 18/64 (28.1%) | 61/64 (95.3%) |
| Pemetrexed + Carboplatin | — | 5/54 (9.3%) | 52/54 (96.3%) |
| Event | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/64 | 0/54 |
| NauseaGastrointestinal disorders | 4/64 | 0/54 |
| VomitingGastrointestinal disorders | 3/64 | 0/54 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/64 | 0/54 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/64 | 2/54 |
| NeutropeniaBlood and lymphatic system disorders | 2/64 | 0/54 |
| Chest painGeneral disorders | 2/64 | 0/54 |
| Splenic artery aneurysmGastrointestinal disorders | 0/64 | 1/54 |
| BronchitisInfections and infestations | 1/64 | 1/54 |
| Aortic aneurysmVascular disorders | 0/64 | 1/54 |
| Event | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| NauseaGastrointestinal disorders | 40/64 | 30/54 |
| FatigueGeneral disorders | 23/64 | 21/54 |
| NeutropeniaBlood and lymphatic system disorders | 21/64 | 15/54 |
| VomitingGastrointestinal disorders | 21/64 | 17/54 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/64 | 16/54 |
| ConstipationGastrointestinal disorders | 17/64 | 8/54 |
| AnorexiaMetabolism and nutrition disorders | 10/64 | 14/54 |
| AstheniaGeneral disorders | 10/64 | 13/54 |
| AnaemiaBlood and lymphatic system disorders | 12/64 | 8/54 |
| Neutrophil count decreasedInvestigations | 4/64 | 10/54 |
| Age, Continuous(years) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Mean | 60.6 ± 7.7 | 58.9 ± 7.2 | 59.7 ± 7.5 |
| Sex: Female, Male(Participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Female | 14 | 18 | 32 |
| Male | 49 | 41 | 90 |
| Race/Ethnicity, Customized(participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Caucasian | 62 | 58 | 120 |
| African | 1 | 1 | 2 |
| Region of Enrollment(participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| France | 12 | 8 | 20 |
| Spain | 7 | 8 | 15 |
| Germany | 44 | 43 | 87 |
| Curative Surgery Used(participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Pneumonectomy | 9 | 9 | 18 |
| Lobectomy | 46 | 46 | 92 |
| Bi-lobectomy | 8 | 4 | 12 |
| Smoking History(participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Yes | 56 | 56 | 112 |
| No | 7 | 3 | 10 |
| Stage of Disease Prior to Tumor Resection(participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Stage Ia | 0 | 1 | 1 |
| Stage Ib | 27 | 26 | 53 |
| Stage IIa | 6 | 5 | 11 |
| Stage IIb | 30 | 25 | 55 |
| Stage IIIa | 0 | 1 | 1 |
| Unknown: could have been either Stage IIIb or IV | 0 | 1 | 1 |
| Tumor Type at Initial Pathological Diagnosis(participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Adenocarcinoma of the Lung | 27 | 23 | 50 |
| Squamous Carcinoma of the Lung | 24 | 20 | 44 |
| Non-Small Cell Lung Cancer | 5 | 4 | 9 |
| Mixed Cell (Squamous/Adeno) Carcinoma of Lung | 0 | 5 | 5 |
| Large Cell Carcinoma of Lung | 5 | 7 | 12 |
| Bronchoalveolar Carcinoma | 2 | 0 | 2 |
The record gives a start of Dec 2005, a primary completion of Nov 2007 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cisplatin · Carboplatin
Carcinoma, Non-Small-Cell Lung →